MedinCell receives €4 million in funding from Bpifrance and within the framework of the French Recovery Plan (Plan France Relance)
December 1, 2021
Previous PostVideoconference and publication of the 2021-2022 Half-Year Results, on December 8, 2021
Next PostPhase 3 data of mdc-IRM, first product based on MedinCell’s technology, shows significant improvements in patients with schizophrenia: - Prolonged time to impending relapse - Decreased risk of relapse - Increased chance of clinical stability
